Table 1 Clinical characteristics of test and control groups of patients
Test group | Control group | P value | |||||||
|---|---|---|---|---|---|---|---|---|---|
n | % | n | % | ||||||
Age [mean (range)] | 61 (38–80) | 64 (41–80) | 1 | ||||||
Sex | 0.059 | ||||||||
Male | 31 | 96.2 | 18 | 75.0 | |||||
Female | 2 | 3.8 | 6 | 25.0 | |||||
Performance status | 0.444 | ||||||||
0 | 1 | 3.0 | 0 | 0 | |||||
1 | 32 | 97.0 | 19 | 79.2 | |||||
ND | 5 | 20.8 | |||||||
Smoking history | 0.912 | ||||||||
Current smoker | 11 | 33.3 | 9 | 37.5 | |||||
Former smoker | 21 | 63.6 | 14 | 58.3 | |||||
Never smoker | 1 | 3.0 | 1 | 4.2 | |||||
Primary site | 0.952 | ||||||||
Oral cavity | 7 | 21.2 | 6 | 25.0 | |||||
Oropharynx | 7 | 21.2 | 4 | 16.7 | |||||
Hypopharynx | 6 | 18.2 | 4 | 16.7 | |||||
Larynx | 12 | 36.4 | 10 | 41.7 | |||||
ND | 1 | 3.0 | |||||||
Failure sites | |||||||||
Locoregional | 28 | 87.5 | NA | ||||||
Distance | 19 | 59.4 | NA | ||||||
Both | 10 | 31.3 | NA | ||||||
Therapeutic regimen | Lengtha | Follow-upb | Lengtha | Follow-upb | |||||
Cetuximab | 15 | 45.5 | 4–64 (12) | 15–76 (30) | NA | ||||
Cetuximab/platinum/5FU | 13 | 39.4 | 4–56 (22) | 6–74 (33) | NA | ||||
Cetuximab/taxane | 5 | 15.1 | 20–32 (24) | 24–26 (25) | NA | ||||
Chemotherapy (CDDP) | NA | 5 | 20.8 | 3 (3) | 9–121 (40) | ||||
No chemotherapy | 13 | 54.2 | |||||||
ND | 6 | 25 | |||||||
Skin toxicity | |||||||||
Rash grade 1 | 7 | 21.2 | NA | ||||||
Rash grade 2 | 11 | 33.3 | NA | ||||||
Rash grade 3 | 5 | 15.2 | NA | ||||||
ND | 10 | 30.3 | |||||||
Hypomagnesemia | |||||||||
Yes | 6 | 18.2 | |||||||
No | 15 | 45.5 | |||||||
ND | 12 | 36.4 | 24 | ||||||